Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Good morning, Boston, and Happy National Handshake Day. Here are the five things you need to know in local business news to start your busy Thursday.

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

The problems cut across the industry as a whole. Many publicly traded biotech companies are now valued at less than the cash ...

Denali Therapeutics remains an intriguing clinical-stage biotech focused on neurodegenerative and lysosomal storage diseases.

View Biogen Inc. BIIB stock quote prices, financial information, real-time forecasts, and company news from CNN.

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent ...

CAMBRIDGE, MA, USA I June 25, 2025 I Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense ...